Delving into the Latest Updates on SN-29926 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

Proacta, Inc.

Active Organization-

Inactive Organization

Proacta, Inc.

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

The 21st international symposium of the American Association for Cancer Research (AACR), the NCI and the European Organization for Research and Treatment of Cancer (EORTC), held in Boston, included topics covering the development of therapeutics and molecular targets in the field of cancer research. This conference report highlights selected presentations on the development of novel drugs for cancer. Investigational drugs discussed include XL-139 (Bristol-Myers Squibb Co/Exelixis Inc), SPC-3042 (Enzon Pharmaceuticals Inc/ Santaris Pharma A/S), CH-5137291 (Chugai Pharmaceutical Co Ltd), SN-29966/SN-29926/SN-3000 (Proacta Inc), withaferin-A (University of Kansas), Reolysin (Oncolytics Biotech Inc), EZN-3889 and EZN-3892 (Enzon Pharmaceuticals/Santaris Pharma), and CBP-501 (CanBas Co Ltd/Takeda Pharmaceutical Co Ltd).

100 Deals associated with SN-29926

Login to view more data